GLP-1 Receptor Analogs

Limited Access to Popular Weight-Loss Drugs Highlights Socioeconomic Disparities

Despite their effectiveness, GLP-1 drugs remain costly and are only covered by Medicaid in 13 states, raising concerns about equitable access.